The purpose of this study is to examine reports of the cancer called hepatosplenic T-cell lymphoma (HSTCL) in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief or PALGA) during the years 1995 to 2008.
This is a observational, retrospective (a study in which the participants are identified and then followed backward in time, for the outcome of the study) study. In this study review of all reports of possible cases of hepatosplenic T-cell lymphoma (HSTCL) that were identified within the PALGA database of pathology results for The Netherlands from 1995 to 2008. All patients whose information is contained within the PALGA database were prescribed treatments by a physician on the basis of usual clinical practice or may have received other treatments, including experimental drugs, while participating in an interventional clinical study. The identified data on each of the patients with reports of HSTCL will be collected from the pathologist(s) who prepared the report and from the physician(s) who treated the patient at the time of diagnosis.
Study Type
OBSERVATIONAL
Enrollment
15
This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
Unnamed facility
Alkmaar, Netherlands
Unnamed facility
Amsterdam, Netherlands
Unnamed facility
Amsterdam-Zuidoost, Netherlands
Unnamed facility
Eindhoven, Netherlands
Number of patients with diagnosis of Hepatosplenic T-cell Lymphoma (HSTCL)
Evaluation of the occurrence of the diagnosis of HSTCL among patients with pathology reports in the Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (PALGA) database during the years 1995 to 2008.
Time frame: 1 year
Number of patients with HSTCL that are present in the population of The Netherlands
Number of cases with HSTCL will be used to evaluate the prevalence.
Time frame: 1 year
Number of newly diagnosed patients with HSTCL that are present in the population of The Netherlands
Number of newly diagnosed patients with HSTCL will be used to evaluate the incidence of HSTCL.
Time frame: 1 year
Number of newly diagnosed patients with HSTCL that are present in the population of The Netherlands prior to and after the availability of infliximab
Number of newly diagnosed patients with HSTCL will be used to evaluate the incidence of HSTCL prior to and after the availability of infliximab.
Time frame: 1 year
Data collection for factors associated with the diagnosis of HSTCL
Data collection will include HSCTL diagnosis, diseases and medical/surgical conditions, cytogenetic data, and demographic data.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Groningen, Netherlands
Unnamed facility
Nijmegen, Netherlands
Unnamed facility
Oss, Netherlands
Unnamed facility
Rotterdam, Netherlands
Unnamed facility
Utrecht, Netherlands
Unnamed facility
Winschoten, Netherlands